Structure-guided drug design
Innovimmune discovers and develops its proprietary New Chemical Entity (NCE) pipeline of oral small-molecule medicines.
Enabling intractable disease-modifying proteins to be druggable targets
Only a much smaller fraction of human proteins are currently drugged that are approved and available to treat patients. Important disease-causing proteins have traditionally been highlighted as intractable to small-molecule drugs. We discover new medicines by enabling intractable disease-modifying proteins to become druggable therapeutic targets using structure-guided drug design coupled with fragment-based drug design. We design synthetic compounds from detailed three-dimensional structural knowledge and active site characteristics of drug targets associated with cancer and inflammatory diseases. We integrate the disciplines of structural biology, X-ray crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals.
Utilizing stringent Lipinski Rule-of-Five
These discovery efforts allow our scientists to provide details of protein-ligand interactions and binding sites that inform chemical tractability, downstream biology, simultaneously generate clinical candidate selection compounds, and expansion of our broad intellectual property portfolio. Our proprietary compounds bind to pharmacophoric binding sites and inactivate disease-associated protein targets with unrivaled precision down to Angstrom level resolution. Utilizing Lipinski Rule-of-Five compliance, we achieve drug likeness, minimal toxicity and drug-drug-interactions, optimal bioavailability and enhanced efficacy. Our goal is to deliver highly efficacious and safe novel treatments to our patients suffering with Cancer, Autoimmune Diseases and Inflammation.